Industry Research Reports
Home > Reports > Service & Software > Global Genetic Disease Testing Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Genetic Disease Testing Market Outlook, In‑Depth Analysis & Forecast to 2032
Industry: Service & Software
Published Date: 2026-03-11
Pages: 145 Pages
Report ld: 6202189
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Genetic Disease Testing Market Size(US$)
CAGR 2026-2032
11.5%
Market Size,2032
USD 2,267
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 1,178 million
Market Forecast in 2032(Value)
US$ 2,267 million
CAGR
11.5%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Genetic Disease Testing market is projected to grow from US$ 1067 million in 2025 to US$ 2267 million by 2032, at a CAGR of 11.5% (2026-2032), driven by critical product segments and diverse end‑use applications.
Genetic disease testing, also known as genetic testing, involves analyzing chromosomes, genes, or proteins to identify changes that may lead to genetic disorders. This testing can confirm or rule out suspected genetic conditions or assess the risk of developing or passing on genetic disorders.
Market Development Overview:
In recent years, the genetic disease testing market has seen substantial growth due to advances in genomics, increased awareness of genetic diseases, and growing demand for personalized medicine. The global genetic disease testing market was valued at billions of dollars in 2023 and is expected to expand at a significant compound annual growth rate (CAGR) in the coming years. Factors driving this growth include technological advances in next-generation sequencing (NGS), declining costs of genetic testing, and expanding applications in oncology, rare disease diagnosis, and reproductive health. Governments and healthcare organizations around the world are actively promoting genetic screening programs, further driving market expansion. Direct-to-consumer (DTC) genetic testing is also becoming increasingly popular, with companies offering home testing kits for health risk assessment and ancestry tracing. The market is expected to maintain steady growth as regulators create clearer guidelines for genetic testing services.
Market Development Opportunities:
Next-generation sequencing (NGS) and CRISPR gene editing technologies are revolutionizing genetic testing, enabling faster, more accurate, and more cost-effective diagnoses. The reduction in the cost of whole genome sequencing makes genetic testing more accessible to a wider range of people. As healthcare shifts toward personalized treatment plans, genetic testing is becoming an important tool to tailor treatments to patients’ genetic profiles. Precision oncology in particular benefits from genetic insights that enable targeted cancer treatments. Many rare genetic diseases remain undiagnosed due to the complexity of traditional diagnostic methods. Advances in genetic testing are improving early detection and management of these diseases, creating new market opportunities. With consumers’ growing interest in health and ancestry, demand for direct-to-consumer genetic testing companies has surged. Companies are also developing AI-driven analytics to provide more personalized insights from genetic data.
Market Risks and Challenges:
Genetic testing raises ethical questions about data privacy, consent, and potential misuse of genetic information. Governments are implementing stricter regulations, which could impact market growth if compliance costs increase. As genetic testing companies collect large amounts of sensitive personal data, the risk of data breaches and misuse continues to increase. Ensuring secure storage and ethical use of genetic data is a key concern for industry stakeholders. Despite declining sequencing costs, genetic testing remains expensive in many regions, limiting accessibility to low-income populations. Insurance coverage for genetic testing also varies, impacting adoption rates. Without appropriate genetic counseling, consumers and patients may misinterpret test results, leading to unnecessary anxiety or inappropriate medical decisions. Expanding access to genetic counseling services is critical to mitigating this risk.
Report Includes:
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Genetic Disease Testing market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Invitae
- Ambry Genetics
- Exact Sciences
- Qiagen
- Tempus
- 23andme
- Veritas Genetics
- Myriad Genetics
- LabCorp
- Blueprint Genetics
- Illumina
- CENTOGENE
- GeneDx
- Fulgent Genetics
- BGI Genomics
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Direct Genetic Testing
- Indirect Genetic Testing
Segment by Application
- Carrier Testing
- Prenatal Testing
- Newborn Screening
- Others
CHAPTER OUTLINE
Chapter 1: Defines the Genetic Disease Testing study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Genetic Disease Testing: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Genetic Disease Testing Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Direct Genetic Testing
1.2.3 Indirect Genetic Testing
1.3 Market Segmentation by Application
1.3.1 Global Genetic Disease Testing Market Size by Application, 2021 vs 2025 vs 2032
1.3.2 Carrier Testing
1.3.3 Prenatal Testing
1.3.4 Newborn Screening
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Genetic Disease Testing Revenue Estimates and Forecasts (2021-2032)
2.2 Global Genetic Disease Testing Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global Genetic Disease Testing Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Genetic Disease Testing Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Direct Genetic Testing: Market Share by Key Players
3.3.2 Indirect Genetic Testing: Market Share by Key Players
3.4 Global Genetic Disease Testing Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global Genetic Disease Testing Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Genetic Disease Testing Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Genetic Disease Testing Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Genetic Disease Testing Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Genetic Disease Testing Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Genetic Disease Testing Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Genetic Disease Testing Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Genetic Disease Testing Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Genetic Disease Testing Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Genetic Disease Testing Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Genetic Disease Testing Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Genetic Disease Testing Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 Invitae
11.1.1 Invitae Corporation Information
11.1.2 Invitae Business Overview
11.1.3 Invitae Genetic Disease Testing Product Features and Attributes
11.1.4 Invitae Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.1.5 Invitae Genetic Disease Testing Revenue by Product in 2025
11.1.6 Invitae Genetic Disease Testing Revenue by Application in 2025
11.1.7 Invitae Genetic Disease Testing Revenue by Geographic Area in 2025
11.1.8 Invitae Genetic Disease Testing SWOT Analysis
11.1.9 Invitae Recent Developments
11.2 Ambry Genetics
11.2.1 Ambry Genetics Corporation Information
11.2.2 Ambry Genetics Business Overview
11.2.3 Ambry Genetics Genetic Disease Testing Product Features and Attributes
11.2.4 Ambry Genetics Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.2.5 Ambry Genetics Genetic Disease Testing Revenue by Product in 2025
11.2.6 Ambry Genetics Genetic Disease Testing Revenue by Application in 2025
11.2.7 Ambry Genetics Genetic Disease Testing Revenue by Geographic Area in 2025
11.2.8 Ambry Genetics Genetic Disease Testing SWOT Analysis
11.2.9 Ambry Genetics Recent Developments
11.3 Exact Sciences
11.3.1 Exact Sciences Corporation Information
11.3.2 Exact Sciences Business Overview
11.3.3 Exact Sciences Genetic Disease Testing Product Features and Attributes
11.3.4 Exact Sciences Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.3.5 Exact Sciences Genetic Disease Testing Revenue by Product in 2025
11.3.6 Exact Sciences Genetic Disease Testing Revenue by Application in 2025
11.3.7 Exact Sciences Genetic Disease Testing Revenue by Geographic Area in 2025
11.3.8 Exact Sciences Genetic Disease Testing SWOT Analysis
11.3.9 Exact Sciences Recent Developments
11.4 Qiagen
11.4.1 Qiagen Corporation Information
11.4.2 Qiagen Business Overview
11.4.3 Qiagen Genetic Disease Testing Product Features and Attributes
11.4.4 Qiagen Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.4.5 Qiagen Genetic Disease Testing Revenue by Product in 2025
11.4.6 Qiagen Genetic Disease Testing Revenue by Application in 2025
11.4.7 Qiagen Genetic Disease Testing Revenue by Geographic Area in 2025
11.4.8 Qiagen Genetic Disease Testing SWOT Analysis
11.4.9 Qiagen Recent Developments
11.5 Tempus
11.5.1 Tempus Corporation Information
11.5.2 Tempus Business Overview
11.5.3 Tempus Genetic Disease Testing Product Features and Attributes
11.5.4 Tempus Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.5.5 Tempus Genetic Disease Testing Revenue by Product in 2025
11.5.6 Tempus Genetic Disease Testing Revenue by Application in 2025
11.5.7 Tempus Genetic Disease Testing Revenue by Geographic Area in 2025
11.5.8 Tempus Genetic Disease Testing SWOT Analysis
11.5.9 Tempus Recent Developments
11.6 23andme
11.6.1 23andme Corporation Information
11.6.2 23andme Business Overview
11.6.3 23andme Genetic Disease Testing Product Features and Attributes
11.6.4 23andme Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.6.5 23andme Recent Developments
11.7 Veritas Genetics
11.7.1 Veritas Genetics Corporation Information
11.7.2 Veritas Genetics Business Overview
11.7.3 Veritas Genetics Genetic Disease Testing Product Features and Attributes
11.7.4 Veritas Genetics Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.7.5 Veritas Genetics Recent Developments
11.8 Myriad Genetics
11.8.1 Myriad Genetics Corporation Information
11.8.2 Myriad Genetics Business Overview
11.8.3 Myriad Genetics Genetic Disease Testing Product Features and Attributes
11.8.4 Myriad Genetics Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.8.5 Myriad Genetics Recent Developments
11.9 LabCorp
11.9.1 LabCorp Corporation Information
11.9.2 LabCorp Business Overview
11.9.3 LabCorp Genetic Disease Testing Product Features and Attributes
11.9.4 LabCorp Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.9.5 LabCorp Recent Developments
11.10 Blueprint Genetics
11.10.1 Blueprint Genetics Corporation Information
11.10.2 Blueprint Genetics Business Overview
11.10.3 Blueprint Genetics Genetic Disease Testing Product Features and Attributes
11.10.4 Blueprint Genetics Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Illumina
11.11.1 Illumina Corporation Information
11.11.2 Illumina Business Overview
11.11.3 Illumina Genetic Disease Testing Product Features and Attributes
11.11.4 Illumina Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.11.5 Illumina Recent Developments
11.12 CENTOGENE
11.12.1 CENTOGENE Corporation Information
11.12.2 CENTOGENE Business Overview
11.12.3 CENTOGENE Genetic Disease Testing Product Features and Attributes
11.12.4 CENTOGENE Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.12.5 CENTOGENE Recent Developments
11.13 GeneDx
11.13.1 GeneDx Corporation Information
11.13.2 GeneDx Business Overview
11.13.3 GeneDx Genetic Disease Testing Product Features and Attributes
11.13.4 GeneDx Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.13.5 GeneDx Recent Developments
11.14 Fulgent Genetics
11.14.1 Fulgent Genetics Corporation Information
11.14.2 Fulgent Genetics Business Overview
11.14.3 Fulgent Genetics Genetic Disease Testing Product Features and Attributes
11.14.4 Fulgent Genetics Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.14.5 Fulgent Genetics Recent Developments
11.15 BGI Genomics
11.15.1 BGI Genomics Corporation Information
11.15.2 BGI Genomics Business Overview
11.15.3 BGI Genomics Genetic Disease Testing Product Features and Attributes
11.15.4 BGI Genomics Genetic Disease Testing Revenue and Gross Margin (2021-2026)
11.15.5 BGI Genomics Recent Developments
12 Genetic Disease Testing Value Chain and Ecosystem Analysis
12.1 Genetic Disease Testing Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Genetic Disease Testing Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Genetic Disease Testing Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Genetic Disease Testing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Genetic Disease Testing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Genetic Disease Testing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Genetic Disease Testing Revenue by Region (US$ Million), 2021-2026
Table 5. Global Genetic Disease Testing Revenue by Region (US$ Million), 2027-2032
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 7. Global Genetic Disease Testing Revenue by Players (US$ Million), 2021-2026
Table 8. Global Genetic Disease Testing Revenue-Based Market Share by Players (2021-2026)
Table 9. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 10. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Genetic Disease Testing Revenue, 2025
Table 11. Global Genetic Disease Testing Average Gross Margin (%) by Player (2021 vs 2025)
Table 12. Global Genetic Disease Testing Companies Headquarters
Table 13. Global Genetic Disease Testing Market Concentration Ratio (CR5)
Table 14. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Genetic Disease Testing Revenue by Type (US$ Million), 2021-2026
Table 17. Global Genetic Disease Testing Revenue by Type (US$ Million), 2027-2032
Table 18. Key Product Attributes and Differentiation
Table 19. Global Genetic Disease Testing Revenue by Application (US$ Million), 2021-2026
Table 20. Global Genetic Disease Testing Revenue by Application (US$ Million), 2027-2032
Table 21. Genetic Disease Testing High-Growth Sectors Demand CAGR (2026-2032)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Genetic Disease Testing Growth Accelerators and Market Barriers
Table 25. North America Genetic Disease Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 26. Europe Genetic Disease Testing Growth Accelerators and Market Barriers
Table 27. Europe Genetic Disease Testing Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. Asia-Pacific Genetic Disease Testing Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Genetic Disease Testing Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 30. Central and South America Genetic Disease Testing Investment Opportunities and Key Challenges
Table 31. Central and South America Genetic Disease Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Middle East and Africa Genetic Disease Testing Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Genetic Disease Testing Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 34. Invitae Corporation Information
Table 35. Invitae Description and Major Businesses
Table 36. Invitae Product Features and Attributes
Table 37. Invitae Revenue (US$ Million) and Gross Margin (2021-2026)
Table 38. Invitae Revenue Proportion by Product in 2025
Table 39. Invitae Revenue Proportion by Application in 2025
Table 40. Invitae Revenue Proportion by Geographic Area in 2025
Table 41. Invitae Genetic Disease Testing SWOT Analysis
Table 42. Invitae Recent Developments
Table 43. Ambry Genetics Corporation Information
Table 44. Ambry Genetics Description and Major Businesses
Table 45. Ambry Genetics Product Features and Attributes
Table 46. Ambry Genetics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 47. Ambry Genetics Revenue Proportion by Product in 2025
Table 48. Ambry Genetics Revenue Proportion by Application in 2025
Table 49. Ambry Genetics Revenue Proportion by Geographic Area in 2025
Table 50. Ambry Genetics Genetic Disease Testing SWOT Analysis
Table 51. Ambry Genetics Recent Developments
Table 52. Exact Sciences Corporation Information
Table 53. Exact Sciences Description and Major Businesses
Table 54. Exact Sciences Product Features and Attributes
Table 55. Exact Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
Table 56. Exact Sciences Revenue Proportion by Product in 2025
Table 57. Exact Sciences Revenue Proportion by Application in 2025
Table 58. Exact Sciences Revenue Proportion by Geographic Area in 2025
Table 59. Exact Sciences Genetic Disease Testing SWOT Analysis
Table 60. Exact Sciences Recent Developments
Table 61. Qiagen Corporation Information
Table 62. Qiagen Description and Major Businesses
Table 63. Qiagen Product Features and Attributes
Table 64. Qiagen Revenue (US$ Million) and Gross Margin (2021-2026)
Table 65. Qiagen Revenue Proportion by Product in 2025
Table 66. Qiagen Revenue Proportion by Application in 2025
Table 67. Qiagen Revenue Proportion by Geographic Area in 2025
Table 68. Qiagen Genetic Disease Testing SWOT Analysis
Table 69. Qiagen Recent Developments
Table 70. Tempus Corporation Information
Table 71. Tempus Description and Major Businesses
Table 72. Tempus Product Features and Attributes
Table 73. Tempus Revenue (US$ Million) and Gross Margin (2021-2026)
Table 74. Tempus Revenue Proportion by Product in 2025
Table 75. Tempus Revenue Proportion by Application in 2025
Table 76. Tempus Revenue Proportion by Geographic Area in 2025
Table 77. Tempus Genetic Disease Testing SWOT Analysis
Table 78. Tempus Recent Developments
Table 79. 23andme Corporation Information
Table 80. 23andme Description and Major Businesses
Table 81. 23andme Product Features and Attributes
Table 82. 23andme Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. 23andme Recent Developments
Table 84. Veritas Genetics Corporation Information
Table 85. Veritas Genetics Description and Major Businesses
Table 86. Veritas Genetics Product Features and Attributes
Table 87. Veritas Genetics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Veritas Genetics Recent Developments
Table 89. Myriad Genetics Corporation Information
Table 90. Myriad Genetics Description and Major Businesses
Table 91. Myriad Genetics Product Features and Attributes
Table 92. Myriad Genetics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. Myriad Genetics Recent Developments
Table 94. LabCorp Corporation Information
Table 95. LabCorp Description and Major Businesses
Table 96. LabCorp Product Features and Attributes
Table 97. LabCorp Revenue (US$ Million) and Gross Margin (2021-2026)
Table 98. LabCorp Recent Developments
Table 99. Blueprint Genetics Corporation Information
Table 100. Blueprint Genetics Description and Major Businesses
Table 101. Blueprint Genetics Product Features and Attributes
Table 102. Blueprint Genetics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 103. Blueprint Genetics Recent Developments
Table 104. Illumina Corporation Information
Table 105. Illumina Description and Major Businesses
Table 106. Illumina Product Features and Attributes
Table 107. Illumina Revenue (US$ Million) and Gross Margin (2021-2026)
Table 108. Illumina Recent Developments
Table 109. CENTOGENE Corporation Information
Table 110. CENTOGENE Description and Major Businesses
Table 111. CENTOGENE Product Features and Attributes
Table 112. CENTOGENE Revenue (US$ Million) and Gross Margin (2021-2026)
Table 113. CENTOGENE Recent Developments
Table 114. GeneDx Corporation Information
Table 115. GeneDx Description and Major Businesses
Table 116. GeneDx Product Features and Attributes
Table 117. GeneDx Revenue (US$ Million) and Gross Margin (2021-2026)
Table 118. GeneDx Recent Developments
Table 119. Fulgent Genetics Corporation Information
Table 120. Fulgent Genetics Description and Major Businesses
Table 121. Fulgent Genetics Product Features and Attributes
Table 122. Fulgent Genetics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 123. Fulgent Genetics Recent Developments
Table 124. BGI Genomics Corporation Information
Table 125. BGI Genomics Description and Major Businesses
Table 126. BGI Genomics Product Features and Attributes
Table 127. BGI Genomics Revenue (US$ Million) and Gross Margin (2021-2026)
Table 128. BGI Genomics Recent Developments
Table 129. Technologies, Platforms and Infrastructure
Table 130. Distributors List
Table 131. Market Trends and Market Evolution
Table 132. Market Drivers and Opportunities
Table 133. Market Challenges, Risks, and Restraints
Table 134. Research Programs/Design for This Report
Table 135. Key Data Information from Secondary Sources
Table 136. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Genetic Disease Testing Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Direct Genetic Testing Product Picture
Figure 3. Indirect Genetic Testing Product Picture
Figure 4. Global Genetic Disease Testing Market Size Growth Rate , 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Global Genetic Disease Testing Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 6. Carrier Testing
Figure 7. Prenatal Testing
Figure 8. Newborn Screening
Figure 9. Others
Figure 10. Genetic Disease Testing Report Years Considered
Figure 11. Global Genetic Disease Testing Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 13. Global Genetic Disease Testing Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 14. Global Genetic Disease Testing Revenue-Based Market Share by Region (2021-2032)
Figure 15. Global Genetic Disease Testing Revenue-Based Market Share Ranking (2025)
Figure 16. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 17. Direct Genetic Testing Revenue-Based Market Share by Player in 2025
Figure 18. Indirect Genetic Testing Revenue-Based Market Share by Player in 2025
Figure 19. Global Genetic Disease Testing Revenue-Based Market Share by Type (2021-2032)
Figure 20. Global Genetic Disease Testing Revenue-Based Market Share by Application (2021-2032)
Figure 21. North America Genetic Disease Testing Revenue YoY (US$ Million), 2021-2032
Figure 22. North America Top 5 Players Genetic Disease Testing Revenue (US$ Million) in 2025
Figure 23. North America Genetic Disease Testing Revenue (US$ Million) by Application (2021-2032)
Figure 24. US Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 25. Canada Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 26. Mexico Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 27. Europe Genetic Disease Testing Revenue YoY (US$ Million), 2021-2032
Figure 28. Europe Top 5 Players Genetic Disease Testing Revenue (US$ Million) in 2025
Figure 29. Europe Genetic Disease Testing Revenue (US$ Million) by Application (2021-2032)
Figure 30. Germany Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 31. France Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 32. U.K. Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 33. Italy Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 34. Russia Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 35. Asia-Pacific Genetic Disease Testing Revenue YoY (US$ Million), 2021-2032
Figure 36. Asia-Pacific Top 8 Players Genetic Disease Testing Revenue (US$ Million) in 2025
Figure 37. Asia-Pacific Genetic Disease Testing Revenue (US$ Million) by Application (2021-2032)
Figure 38. Indonesia Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 39. Japan Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 40. South Korea Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 41. Australia Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 42. India Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 43. Indonesia Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 44. Vietnam Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 45. Malaysia Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 46. Philippines Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 47. Singapore Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 48. Central and South America Genetic Disease Testing Revenue YoY (US$ Million), 2021-2032
Figure 49. Central and South America Top 5 Players Genetic Disease Testing Revenue (US$ Million) in 2025
Figure 50. Central and South America Genetic Disease Testing Revenue (US$ Million) by Application (2021-2032)
Figure 51. Brazil Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 52. Argentina Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 53. Middle East and Africa Genetic Disease Testing Revenue YoY (US$ Million), 2021-2032
Figure 54. Middle East and Africa Top 5 Players Genetic Disease Testing Revenue (US$ Million) in 2025
Figure 55. Middle East and Africa Genetic Disease Testing Revenue (US$ Million) by Application (2021-2032)
Figure 56. GCC Countries Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 57. Israel Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 58. Egypt Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 59. South Africa Genetic Disease Testing Revenue (US$ Million), 2021-2032
Figure 60. Genetic Disease Testing Value Chain Mapping
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What is the annual compound growth rate of the global Genetic Disease Testing market size from 2026 to 2032?
The annual compound growth rate of the global Genetic Disease Testing market is 11.5% 2026 to 2032.
What was the global market size of Genetic Disease Testing in 2032?
What was the global market size of Genetic Disease Testing in 2026?
Which companies rank high in the global Genetic Disease Testing market?
Which region is expected to have the highest market share?
Related Reports
Global Genetic Disease Testing Market Research Report 2026
The global Genetic Disease Testing market was valued at US$ 1067 million in 2025 and is anticipated to reach US$ 2267 million by 2032, at a CAGR of 11.5% from 2026 to 2032.
Published Date: 2026-03-11
Pages: 111
USD 2900.00
(Single User License)
Global Genetic Disease Testing Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Genetic Disease Testing market size was US$ 1067 million in 2025 and is forecast to reach a readjusted size of US$ 2267 million by 2032 with a CAGR of 11.5% during the forecast period 2026-2032.
Published Date: 2026-03-11
Pages: 94
USD 4250.00
(Single User License)
Genetic Disease Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Genetic Disease Testing was estimated to be worth US$ 1067 million in 2025 and is projected to reach US$ 2267 million, growing at a CAGR of 11.5% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 106
USD 3950.00
(Single User License)
Global Genetic Disease Testing Market Insights, Forecast to 2031
The global Genetic Disease Testing market is projected to grow from US$ 1067 million in 2025 to US$ 2054 million by 2031, at a Compound Annual Growth Rate (CAGR) of 11.5% during the forecast period.
Published Date: 2025-03-28
Pages: 132
USD 4900.00
(Single User License)
Global Genetic Disease Testing Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Genetic Disease Testing market size was US$ 1026 million in 2024 and is forecast to a readjusted size of US$ 2054 million by 2031 with a CAGR of 11.5% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 95
USD 4250.00
(Single User License)
Global Genetic Disease Testing Market Research Report 2025
The global market for Genetic Disease Testing was valued at US$ 1026 million in the year 2024 and is projected to reach a revised size of US$ 2054 million by 2031, growing at a CAGR of 11.5% during the forecast period.
Published Date: 2025-03-28
Pages: 87
USD 2900.00
(Single User License)
Genetic Disease Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Genetic Disease Testing was estimated to be worth US$ 1026 million in 2024 and is forecast to a readjusted size of US$ 2054 million by 2031 with a CAGR of 11.5% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 101
USD 3950.00
(Single User License)
Global Genetic Disease Testing Market Research Report 2026
The global Genetic Disease Testing market was valued at US$ 1067 million in 2025 and is anticipated to reach US$ 2267 million by 2032, at a CAGR of 11.5% from 2026 to 2032.
Published: 2026-03-11
Pages: 111
USD 2900.00 (Single User License)Global Genetic Disease Testing Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Genetic Disease Testing market size was US$ 1067 million in 2025 and is forecast to reach a readjusted size of US$ 2267 million by 2032 with a CAGR of 11.5% during the forecast period 2026-2032.
Published: 2026-03-11
Pages: 94
USD 4250.00 (Single User License)Genetic Disease Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Genetic Disease Testing was estimated to be worth US$ 1067 million in 2025 and is projected to reach US$ 2267 million, growing at a CAGR of 11.5% from 2026 to 2032.
Published: 2026-03-09
Pages: 106
USD 3950.00 (Single User License)Global Genetic Disease Testing Market Insights, Forecast to 2031
The global Genetic Disease Testing market is projected to grow from US$ 1067 million in 2025 to US$ 2054 million by 2031, at a Compound Annual Growth Rate (CAGR) of 11.5% during the forecast period.
Published: 2025-03-28
Pages: 132
USD 4900.00 (Single User License)Global Genetic Disease Testing Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Genetic Disease Testing market size was US$ 1026 million in 2024 and is forecast to a readjusted size of US$ 2054 million by 2031 with a CAGR of 11.5% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 95
USD 4250.00 (Single User License)Global Genetic Disease Testing Market Research Report 2025
The global market for Genetic Disease Testing was valued at US$ 1026 million in the year 2024 and is projected to reach a revised size of US$ 2054 million by 2031, growing at a CAGR of 11.5% during the forecast period.
Published: 2025-03-28
Pages: 87
USD 2900.00 (Single User License)Genetic Disease Testing - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Genetic Disease Testing was estimated to be worth US$ 1026 million in 2024 and is forecast to a readjusted size of US$ 2054 million by 2031 with a CAGR of 11.5% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 101
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now